Gables Capital Management Inc. Outlook Therapeutics, Inc. Transaction History

Gables Capital Management Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$0.22 - $0.66 $1,760 - $5,280	-8,000 Reduced 5.18%	146,500 $57,000
Q3 2023 Nov 02, 2023	BUY	$0.2 - $1.78 $17,600 - $156,640	88,000 Added 132.33%	154,500 $33,000
Q4 2022 Feb 03, 2023	BUY	$0.87 - $1.33 $4,350 - $6,650	5,000 Added 8.13%	66,500 $71,000
Q2 2022 Jul 18, 2022	BUY	$0.91 - $2.01 $13,650 - $30,149	15,000 Added 32.26%	61,500 $63,000
Q1 2022 May 02, 2022	BUY	$1.22 - $2.03 $52,460 - $87,289	43,000 Added 1228.57%	46,500 $83,000
Q4 2021 Feb 09, 2022	BUY	$1.27 - $2.23 $4,445 - $7,805	3,500 New	3,500 $5,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Gables Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Gables Capital Management Inc. with notifications on news.